Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Single- and Multiple-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab® PCA System (Zalviso™) in Healthy Subjects

Determine the plasma concentration profile after single and multiple dosing of Sufentanil NanoTabs

Inclusion Criteria:

• Non smoking
• Ages 18 to 45 year, inclusive
• BMI between 18 and 30

Exclusion Criteria:

• Subjects taking any prescription or OTC medications or vitamins or supplements
• Pregnant females
• Subjects with pulmonary disease or sleep apnea